<DOC>
	<DOC>NCT00168883</DOC>
	<brief_summary>This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.</brief_summary>
	<brief_title>Study for Patients With Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>Randomized Phase II design, multicenter study, to assess the efficacy and safety of combined chemotherapy with Paclitaxel and Carboplatin versus a platinum free chemotherapy with Paclitaxel and Vinorelbine, within the combination therapies there are two different dosing intervals, which will be assessed as well (4 Arm study).</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Chemotherapy naive patients with histologically confirmed NSCLC stage III and IV New York Heart Association (NYHA) III or IV Brain metastases Neurotoxicity Grade 2 or greater</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>curative non-treatable NSCLC UICC stage IIIB and IV</keyword>
</DOC>